Business
2015 Annual Report and Accounts and Notice of AGM
2015 Annual Report and Accounts and Notice of AGM.
About this update from Shield Therapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 8817C Shield Therapeutics PLC 30 June 2016 \n\n \n \n \n \nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\n \n2015 Annual Report and Accounts and AGM Notification\n \nLondon, UK, 30 June 2016. Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical Company focused on secondary care, gives notice that copies of the 2015 Annual Report and Accounts have been sent to shareholders. This document is available on the \"Investors\" section of the Company's website at www.shieldtherapeutics.com. Shield announced preliminary results for the year ended 31 December 2015 on 14 June 2016.\n \nFurther copies of the Annual Report will be available from the Company Secretary, Shield Therapeutics, Northern Design Centre, Gateshead Quays, NE8 3DF.\n \nShield also announces that its Annual General Meeting will be held on 4 August 2016. The meeting will be held at Stephenson Harwood LLP, 1 Finsbury Circus, London EC2M 7SH, commencing at 10.00 am. Notice of the Annual General Meeting will be sent to shareholders by Monday 11th July 2016.\n \n- Ends -\n \nFor further information please contact:\n \n\n\n\n\nShield Therapeutics plc\n\n\n+44 (0)191 511 8507\n\n\n\n\nCarl Sterritt, Chief Executive Officer\nRichard Jones, Chief Financial Officer\n \n\n\n\n\n\n\n\nNOMAD\nLiberum Capital Limited\nChristopher Britton/Steve Pearce\n \n\n\n+44 (0)20 3100 2222\n\n\n\n\nFinancial PR Advisor\nConsilium Strategic Communications\n\n\n+44 (0)203 709 5700\[email protected]\n\n\n\n\nMary-Jane Elliott/Matthew Neal/Lindsey Neville/Hendrik Thys\n\n\n\n\n\n\n\n \nAbout Shield Therapeutics plc\nShield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The Company has a marketed product, Feraccru®, for the treatment of iron deficiency anaemia (IDA). In addition, the Company has a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia), PT20. Shield, based in London and Newcastle, joined LSE's AIM in 2016 under the ticker STX. For more information please visit www.shieldtherapeutics.com.\n \n\nThis information is provided ...